Showing results (1511-1520 of 2,038) with videos related to

Sort By:
Pageof 204
Nature Communications|December 13, 2024
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostateXuanrong Chen, Michael A Augello, Deli Liu, et al.
The Journal of Clinical Investigation|December 5, 2017
Differential impact of RB status on E2F1 reprogramming in human cancerChristopher McNair, Kexin Xu, Amy C Mandigo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United StatesB A Mahal, Y-W Chen, V Muralidhar, et al.
Physical Review Letters|July 22, 2015
Imaging Molecular Motion: Femtosecond X-Ray Scattering of an Electrocyclic Chemical ReactionM P Minitti, J M Budarz, A Kirrander, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
BJU International|July 16, 2017
Erectile function after stereotactic body radiotherapy for localized prostate cancerRobert T Dess, Holly E Hartman, Nima Aghdam, et al.
Molecular Cancer Research : MCR|February 18, 2018
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic SignatureUdit Singhal, Yugang Wang, James Henderson, et al.
The Prostate|June 3, 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Pageof 204